GentiBio

GentiBio is an early-stage biotherapeutics company co-founded by pioneers in Treg biology and synthetic immunology, aiming to develop engineered regulatory T cells (EngTregs) programmed as immune tolerance drugs for treating autoimmune, alloimmune, autoinflammatory, and allergic diseases. GentiBio, Inc.'s proprietary autologous and allogeneic EngTregs platform integrates key complementary technologies required to successfully restore immune tolerance and overcome the main limitations of existing regulatory T-cell therapies. GentiBio is at the forefront of leveraging a unique therapeutic approach that addresses the root causes of numerous diseases resulting from an overactive and/or dysfunctional immune system.